Published in Sociol Health Illn on November 01, 2006
Comparing family members' motivations and attitudes towards genetic testing for hereditary breast and ovarian cancer: a qualitative analysis. Eur J Hum Genet (2010) 0.99
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet (2013) 0.96
The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns (2008) 0.88
Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families. J Genet Couns (2011) 0.85
Enacting genetic responsibility: experiences of mothers who carry the fragile X gene. Sociol Health Illn (2010) 0.85
Men in the women's world of hereditary breast and ovarian cancer--a systematic review. Fam Cancer (2009) 0.84
Holding blame at bay? 'Gene talk' in family members' accounts of schizophrenia aetiology. Biosocieties (2012) 0.82
Genetics: breast cancer as an exemplar. Nurs Clin North Am (2009) 0.78
"Awakening to" a new meaning of being at-risk for arrhythmogenic right ventricular cardiomyopathy: a grounded theory study. J Community Genet (2015) 0.77
Anticipated stigma and blameless guilt: Mothers' evaluation of life with the sex-linked disorder, hypohidrotic ectodermal dysplasia (XHED). Soc Sci Med (2016) 0.76
Cancer worry among Norwegian male BRCA1/2 mutation carriers. Fam Cancer (2011) 0.75
Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining. J Behav Med (2017) 0.75
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut (2010) 6.34
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Early outcomes of active surveillance for localized prostate cancer. BJU Int (2005) 1.84
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer (2007) 1.84
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res (2006) 1.77
Listening to the views of people affected by cancer about cancer research: an example of participatory research in setting the cancer research agenda. Health Expect (2006) 1.75
A pilot study of compositional analysis of the breast and estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imaging. Cancer Epidemiol Biomarkers Prev (2008) 1.70
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Psychooncology (2003) 1.47
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer (2007) 1.45
Evidence for a colorectal cancer susceptibility locus on chromosome 3q21-q24 from a high-density SNP genome-wide linkage scan. Hum Mol Genet (2006) 1.42
Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab (2007) 1.41
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
An evaluation of research capacity building from the Cancer Experiences Collaborative. BMJ Support Palliat Care (2012) 1.41
Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Hum Mol Genet (2008) 1.40
Developing a policy for paediatric biobanks: principles for good practice. Eur J Hum Genet (2012) 1.39
We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC). Psychooncology (2004) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.37
Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep (2009) 1.32
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Feasibility and acceptability of providing nurse counsellor genetics clinics in primary care. J Adv Nurs (2006) 1.21
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet (2007) 1.20
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Genetic professionals' reports of nondisclosure of genetic risk information within families. Eur J Hum Genet (2005) 1.18
The IPOS new International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. Psychooncology (2011) 1.18
Critical appraisal guidelines for assessing the quality and impact of user involvement in research. Health Expect (2010) 1.13
Deciphering the genetics of hereditary non-syndromic colorectal cancer. Eur J Hum Genet (2008) 1.13
Consent and confidentiality in clinical genetic practice: guidance on genetic testing and sharing genetic information. Clin Med (2012) 1.12
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer (2010) 1.10
Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int (2007) 1.05
RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. Hum Mutat (2004) 1.05
Distinguishing research from clinical care in cancer genetics: theoretical justifications and practical strategies. Soc Sci Med (2009) 1.03
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin Cancer Res (2004) 1.03
Prevalence and predictors of emotional and behavioural functioning of children where a parent has cancer: a multinational study. Cancer (2009) 1.01
Parental physical illness as a risk for psychosocial maladjustment in children and adolescents: epidemiological findings from a national survey in Germany. Psychosomatics (2007) 1.00
Next generation diagnostics in inherited arrhythmia syndromes : a comparison of two approaches. J Cardiovasc Transl Res (2012) 1.00
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin Cancer Res (2006) 0.99
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res (2014) 0.99
Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet (2011) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
A cohort study of the recovery of health and wellbeing following colorectal cancer (CREW study): protocol paper. BMC Health Serv Res (2012) 0.97
The deliverability, acceptability, and perceived effect of the Macmillan approach to weight loss and eating difficulties: a phase II, cluster-randomized, exploratory trial of a psychosocial intervention for weight- and eating-related distress in people with advanced cancer. J Pain Symptom Manage (2010) 0.96
Psychometric properties of the Chinese version of the Mini-Mental Adjustment to Cancer (MINI-MAC) scale. Psychooncology (2003) 0.95
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet (2013) 0.93
Multinational study of cancer patients and their children: factors associated with family functioning. J Clin Oncol (2008) 0.93
Sequence changes in predicted promoter elements of STK11/LKB1 are unlikely to contribute to Peutz-Jeghers syndrome. BMC Genomics (2005) 0.93
Psychosocial care in cancer: an overview of psychosocial programmes and national cancer plans of countries within the International Federation of Psycho-Oncology Societies. Psychooncology (2012) 0.92
Large genomic deletions in AIP in pituitary adenoma predisposition. J Clin Endocrinol Metab (2008) 0.92
'Over-the-counter' genetic testing: what does it really mean for primary care? Br J Gen Pract (2009) 0.90
Genetic testing for breast and ovarian cancer predisposition: cancer burden and responsibility. J Health Psychol (2002) 0.90
Improving the ascertainment of families at high risk of colorectal cancer: a prospective GP register study. Br J Gen Pract (2004) 0.90
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2014) 0.89
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 0.89
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet (2011) 0.89
Working towards ethical management of genetic testing. Lancet (2002) 0.89
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys (2010) 0.88
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res (2012) 0.88
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate (2010) 0.88
Unusual presentation of Lynch Syndrome. Hered Cancer Clin Pract (2009) 0.87
Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and STK11-negative PJS cases. Genes Chromosomes Cancer (2004) 0.87
Information for decision making by patients with early-stage prostate cancer: a comparison across 9 countries. Med Decis Making (2011) 0.87
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet (2011) 0.87
Impact of cancer on everyday life: a systematic appraisal of the research evidence. Health Expect (2011) 0.87
The NCRI cancer experiences collaborative: defining self management. Eur J Oncol Nurs (2007) 0.86
Genetic medicine and incidental findings: it is more complicated than deciding whether to disclose or not. Genet Med (2013) 0.86
Intrusive cognitions and anxiety in cancer patients. J Psychosom Res (2008) 0.85
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer (2007) 0.84
Intrusive cognitions and their appraisal in anxious cancer patients. Psychooncology (2009) 0.84
Information needs of early-stage prostate cancer patients: a comparison of nine countries. Radiother Oncol (2010) 0.83
Speech-language pathologists' assessment practices for children with suspected speech sound disorders: results of a national survey. Am J Speech Lang Pathol (2007) 0.83
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2011) 0.83
Psychometric analyses of the Mental Adjustment to Cancer (MAC) scale in a Greek palliative care unit. Psychooncology (2005) 0.82
Self-care and end of life care--patients' and carers' experience a qualitative study utilising serial triangulated interviews. Support Care Cancer (2011) 0.82
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res (2010) 0.82
Self care and end of life care in advanced cancer: literature review. Eur J Oncol Nurs (2009) 0.81
The role of helplines in cancer care: intertwining emotional support with information or advice-seeking needs. J Psychosoc Oncol (2014) 0.81
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate (2011) 0.81
A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol (2005) 0.81
Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet (2015) 0.80
No evidence of RET germline mutations in familial pituitary adenoma. J Mol Endocrinol (2010) 0.80
Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol (2005) 0.80
The development of a psychoeducational intervention for women living with an increased risk of breast cancer. Patient Educ Couns (2004) 0.79
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. Int J Radiat Oncol Biol Phys (2004) 0.79
Treatment of CML using IFN-alpha: impact on quality of life. Hematol J (2003) 0.79
A primary care specialist genetics service: a cluster-randomised factorial trial. Br J Gen Pract (2012) 0.78
Psychometric properties of the Dutch version of the Mental Adjustment to Cancer scale in Dutch cancer patients. Psychooncology (2010) 0.78